Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone in schizophrenia patients switching from olanzapine
NCT05213143Phase 4Terminated
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lurasidone in schizophrenia, sponsored by Sumitomo Pharma. Primary endpoint: Mean weight change at 16 weeks. Started Dec 2021; status: terminated.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05213143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05213143.